Quarterly ResultMay 6, 2026, 04:14 PM
Vanda Q1 Total Sales $51.7M, Raises 2026 Revenue Guidance to $240-290M
AI Summary
Vanda Pharmaceuticals reported Q1 2026 total net product sales of $51.7 million, a 3% increase year-over-year, driven by a 26% rise in Fanapt® sales to $29.6 million. The company launched NEREUS™ via a direct-to-consumer platform and received FDA approval for BYSANTI™ for bipolar I disorder and schizophrenia. Vanda also raised its full-year 2026 revenue guidance to $240-$290 million, including $10-$30 million from NEREUS™. The net loss for the quarter was $48.6 million due to continued investment.
Key Highlights
- Q1 2026 total net product sales rose 3% to $51.7 million.
- Fanapt® net product sales increased 26% to $29.6 million.
- NEREUS™ (tradipitant) launched via direct-to-consumer platform.
- BYSANTI™ (milsaperidone) received FDA approval for bipolar I disorder and schizophrenia.
- Full-year 2026 revenue guidance raised to $240-$290 million.
- NEREUS™ 2026 net product sales guidance set at $10-$30 million.
- Q1 2026 net loss was $48.6 million ($0.82 diluted loss per share).
- Imsidolimab BLA for GPP accepted for FDA review with Dec 12, 2026 PDUFA date.